Author

H.-H. Hoffmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:mouse· 1

Frequent Co-Authors

A. Cho· 4 shared A. Gazumyan· 4 shared C. Gaebler· 4 shared F. Muecksch· 4 shared F. Schmidt· 4 shared M. Caskey· 4 shared M. Cipolla· 4 shared T. Hatziioannou· 4 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

A. Cho

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Antiviral innate immune memory in alveolar macrophages following SARS-CoV-2 infection.

A. Lercher, J.-G. Cheong, C. Jiang, H.-H. Hoffmann, A. W. Ashbrook, Y. S. Yin, C. Quirk, E. J. DeGrace, L. Chiriboga, B. R. Rosenberg, S. Z. Josefowicz, C. M. Rice

This study shows that SARS-CoV-2 infection primes alveolar macrophages for enhanced antiviral responses against influenza A virus through epigenetic changes in IFN-I pathways.

bioRxiv · Nov 24, 2023 · PreprintImmunology

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins

Z. Wang, F. Muecksch, A. Cho, C. Gaebler, H.-H. Hoffmann, V. Ramos, S. Zong, M. Cipolla, B. Johnson, F. Schmidt, J. DaSilva, E. Bednarski, T. B. Tanfous, R. Raspe, K. Yao, , M. C. Nussenzweig

The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.

bioRxiv · Feb 1, 2022 · PreprintImmunology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz

The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.

bioRxiv · Jul 21, 2020Microbiology

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz

The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.

bioRxiv · Jun 8, 2020Microbiology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology